VVALENSCLINICAL RESEARCH

Independent clinical research site

Clinical research connected to real patient care.

Valens Clinical Research supports sponsor and CRO studies in pain, psychiatry, cognitive disorders, metabolic health and healthy aging—backed by connected clinical pathways, infusion capability and secure participant intake.

Sponsor inquiries: contact@valensclinicalresearch.com · 202-600-5683

Therapeutic focus

Connected service lines create research-ready pathways

Clinical services and research remain operationally and ethically distinct. With authorization, the network can support outreach and referral; research eligibility, consent and study procedures follow the approved protocol.

Pain & neurology

Chronic pain, neuropathic pain, musculoskeletal conditions and non-opioid or interventional research supported by the MyPainDr referral pathway.

Psychiatry & mental health

Major depression, treatment-resistant depression, anxiety, PTSD and substance-use disorders, with eligibility-based coordination through KetamineHubs.

Metabolic & healthy aging

Obesity, cardiometabolic risk, body composition, functional aging and prevention-related studies supported by Valens longevity services.

Cognitive disorders

Mild cognitive impairment, Alzheimer’s disease, agitation and related caregiver-informed research pathways.

Infusion & procedure studies

Investigational-product administration, monitored observation and protocol-directed procedures supported by trained clinical staff.

Participant access

Community outreach and connected-service referrals for prescreening, enrollment and retention across approved protocols.

For sponsors and CROs

A responsive site from feasibility through closeout

VALENS can evaluate opportunities against population access, clinical capability, staffing, facility requirements and competing studies before making enrollment commitments.

  1. 1. Confidential reviewCDA, protocol synopsis and indication fit.
  2. 2. FeasibilityPopulation, recruitment sources, equipment and timelines.
  3. 3. Start-upBudget, contract, regulatory documents, training and activation.
  4. 4. ConductPrescreening, consent, visits, safety reporting and data quality.
  5. 5. CloseoutReconciliation, records, retention and inspection readiness.

Site capabilities

Built for quality execution

Clinical operations

  • Principal investigator and clinical staff
  • Protocol visits and examinations
  • Infusions and monitored observation
  • Procedure support and referral coordination
  • Specimen processing and temperature-controlled storage

Regulatory & data

  • Start-up and essential-document management
  • Source documentation and eCRF support
  • Query, deviation and CAPA workflows
  • Safety-event escalation
  • Audit-ready record retention

Recruitment & retention

  • Secure participant registry
  • Connected clinical-service outreach
  • Community and referral-network engagement
  • Prescreening and visit coordination
  • Participant communication and retention planning

Operational model

From opportunity review to inspection readiness

VALENS evaluates each opportunity against the protocol, population, staffing, facility, equipment and competing-study requirements before committing to enrollment.

Start-up

  • Confidential disclosure and protocol review
  • Feasibility and enrollment assessment
  • Budget and contract coordination
  • Regulatory document collection
  • Delegation, training and activation readiness

Study conduct

  • Prescreening and consent workflow
  • Protocol visits and source documentation
  • Investigational-product or infusion support
  • Specimen processing and shipment coordination
  • Adverse-event and deviation escalation

Data quality

  • Timely eCRF entry and query response
  • Source-to-CRF consistency review
  • Protocol-compliance monitoring
  • Corrective and preventive action tracking
  • Closeout and record-retention readiness

Participant experience

  • Plain-language visit expectations
  • Transportation and scheduling planning
  • Reminder and retention communication
  • Caregiver coordination when permitted
  • Clear separation from private-pay care

Participant rights

Consent is a process, not just a signature.

Potential participants receive study-specific information about purpose, procedures, foreseeable risks, possible benefits, alternatives, costs, compensation, confidentiality and whom to contact. They may ask questions and may decline or withdraw without losing access to ordinary clinical services.

Before joining

Registry submission and prescreening are not study enrollment. Eligibility is determined only through the approved study process.

During a study

Participants should report health changes, side effects and medication changes and follow protocol instructions.

Research versus care

Investigational procedures may not provide personal benefit and are not a substitute for established treatment unless the protocol specifically provides it.

Industry connection directory

Organizations aligned with VALENS research priorities

These links identify potential collaboration targets and public research resources. Listing does not represent an existing partnership, endorsement or active VALENS study.

For participants

Understand each step before deciding

Joining the registry is not consent to a study and does not guarantee eligibility. If a potentially suitable IRB-approved study is available, research staff will explain the purpose, visits, risks, alternatives, costs and compensation before you decide.

Join secure registry
  1. Share interest securelySelect Clinical Research in the intake.
  2. Initial prescreenStaff reviews basic study criteria with permission.
  3. Informed consentAsk questions before signing the study-specific IRB consent.
  4. ScreeningProtocol assessments determine final eligibility.
  5. Study visitsAttend scheduled visits and report changes or side effects.

Research safeguards

Research participation is voluntary and separate from private-pay care. Declining or leaving a study does not affect access to clinical services.

Only active studies with appropriate IRB approval may enroll participants. Each study uses its own approved consent form; general website or treatment consents do not replace it.

Protected health information is handled through authorized systems and role-based workflows. Emergency concerns should be directed to 911, not the research registry.

Research education

Official clinical-trial resources

FDA: Clinical Trials and Human Subject ProtectionFDA: IRBs and Protection of Human SubjectsClinicalTrials.gov

Bring a study to VALENS

Send the protocol synopsis, indication, phase, target population, expected start date and major facility requirements for an initial capability review.